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Chronic infection with the gram-negative organism Pseudomonas aeruginosa is a leading cause of morbidity
and mortality in human patients, despite high doses of antibiotics used to treat the various diseases this
organism causes. These infections are chronic because P. aeruginosa readily forms biofilms, which are inherently resistant to antibiotics as well as the host’s immune system. Our laboratory has been investigating
specific mutations in P. aeruginosa that regulate biofilm bacterial susceptibility to the host. To continue our
investigation of the role of genetics in bacterial biofilm host resistance, we examined P. aeruginosa biofilms that
lack the flgK gene. This mutant lacks flagella, which results in defects in early biofilm development (up to 36 h).
For these experiments, the flgK-disrupted strain and the parental strain (PA14) were used in a modified version
of the 96-well plate microtiter assay. Biofilms were challenged with freshly isolated human leukocytes for 4 to
6 h and viable bacteria enumerated by CFU. Subsequent to the challenge, both mononuclear cells (monocytes
and lymphocytes) and neutrophils, along with tumor necrosis factor alpha (TNF-␣), were required for optimal
killing of the flgK biofilm bacteria. We identified a cytokine cross talk network between mononuclear cells and
neutrophils that was essential to the production of lactoferrin and bacterial killing. Our data suggest that
TNF-␣ is secreted from mononuclear cells, causing neutrophil activation, resulting in the secretion of bactericidal concentrations of lactoferrin. These results extend previous studies of the importance of lactoferrin in
the innate immune defense against bacterial biofilms.
to antimicrobial agents and to clearance by the human immune
system (23, 35, 36, 40, 44, 48, 54). We recently confirmed a
direct link between Pseudomonas aeruginosa biofilm genetics
and resistance to components of the human innate immune
system (35). During this time, other papers have been published supporting our idea that P. aeruginosa and biofilms in
general manipulate the immune system to their advantage (41,
55, 56). Most recently, O’Toole and colleagues demonstrated
that P. aeruginosa biofilms growing on airway epithelial cells
exhibited decreased virulence in the presence of the antibiotic
tobramycin (1).
The most classic example of Pseudomonas aeruginosa biofilm
infections in humans are those associated with the lungs of
cystic fibrosis (CF) patients, which correlate with increased
morbidity and mortality (11, 13–15, 21, 22, 32, 33, 39, 53). Over
three decades ago, Costerton and others demonstrated that
lung material from CF patients contained P. aeruginosa likely
in the form of biofilms (25, 33). More recently, Singh et al.
showed that biofilms of P. aeruginosa existed in the CF lung
(53). Collectively, these papers underscore the importance of
biofilm formation in vivo and document the inability of the
host’s immune system to clear the infections.
Besides infections in the lungs of CF patients, P. aeruginosa
also wreaks havoc in patients with corneal infections, burn
wounds, implanted medical devices, and human immunodeficiency virus (46). Increased morbidity and mortality in these
infections are linked to the ability of P. aeruginosa to form a
biofilm (44, 45, 55). Schaber and colleagues (50) demonstrated

Through the ability to form biofilms, bacteria change their
susceptibility to antibiotics and the host’s immune system, contributing to chronic infections in humans. It’s estimated that
biofilm infections cost $6.5 billion annually to treat (2). Moreover, most biofilm communities utilize genetically regulated
processes to limit the effectiveness of a broad range of antimicrobial agents, likely resulting in even greater health care costs
(54). Thus, the development of therapy that protects the host,
or augments the clearance of biofilm infections, is vital to
improved patient health and to reducing the cost burden of
these infections. However, the immune response to biofilm
infections is poorly characterized, and these mechanisms must
be elucidated to direct the development of biofilm-specific
therapies.
Although much of the current understanding of host-pathogen interactions came from the study of planktonic bacteria, it
is now clear that bacteria in the environment, including the
human environment, live more often as communities of microorganisms (biofilms) than as single-cell suspensions (12, 44,
47). Bacteria within a biofilm differ from their planktonic counterparts in a number of ways, including an inherent resistance
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the formation of biofilms on a mouse burn model after just 8 h
postinoculation. In a 3-year study in Poland, P. aeruginosa was
the most abundant organism isolated from burn wounds (5).
Additionally, P. aeruginosa biofilm presence in chronic wounds
is a likely culprit for the longevity of these infections by keeping the wound in a chronic state of inflammation (7, 31). These
studies highlight the ubiquitous nature of this opportunistic
pathogen and suggest a much larger role of P. aeruginosa
biofilms in many chronic infections in humans.
Alginate protects biofilm bacteria against macrophage
phagocytosis (35). Besides the physical process of phagocytosis
and the killing of bacteria by macrophages and neutrophils, a
number of other antibacterial effector molecules are important
in host defense. Singh and colleagues have shown that lactoferrin (LTF) prevents biofilm development (52). Over a decade ago, superoxide production by neutrophils was shown to
be decreased in biofilm versus planktonic P. aeruginosa (26,
27). Other oxygen-dependent (nitric oxide [NO]) and oxygenindependent (lysozyme and myeloperoxidase [MPO]) responses are also reduced in magnitude or function in response
to P. aeruginosa biofilms (9, 29, 30). These effector molecules
are important in host defense, yet their effect on biofilm virulence or development, especially how they relate mechanistically, remains understudied. Nonetheless, it is now clear that
genetic regulation within the biofilm bacteria plays a large role
in resistance to the human host.
In Salmonella enterica serovar Typhimurium and Escherichia
coli, mutations in the flgK gene result in a nonmotile phenotype, as flgK is a vital gene involved in flagellar synthesis (24).
This functional defect is also observed in P. aeruginosa. The
lack of flagella in P. aeruginosa decreases the magnitude of
early biofilm formation but does not prevent it (45). This defect is overcome with time as mutants lacking the flgK gene
phenotypically approach wild-type biofilm levels after ⬃36 h of
growth. To determine if this genetic mutation affected biofilm
susceptibility to components of the innate immune system, we
grew biofilms of PA14 and isogenic flgK, challenged them with
freshly isolated human leukocytes, and measured biofilm bacterial survival as previously described (35). In the absence of
functional flagella, P. aeruginosa biofilm bacteria were killed by
human leukocytes. To further dissect the interactions of the
host cells with the biofilms, we developed a novel transwell
biofilm killing assay that allowed for the separation of specific
leukocyte populations (mononuclear cells from neutrophils)
and the analysis of antimicrobial products such as superoxide,
MPO, and LTF. Our data demonstrate that cytokine cross talk,
as well as the production of components of the innate immune
system, is important in generating mechanistic responses that
in this case were able to kill biofilm bacteria that lacked intact
flagella.
MATERIALS AND METHODS
Bacterial strains. P. aeruginosa wild-type strain PA14 and a mutant of this
strain lacking the flgK gene, PA14 flgK::Tn5B30(Tc) (hereby referred to as flgK
throughout this paper), were used in this study. The PA14 strain was grown on
Luria-Bertani (LB) agar and in LB broth for the experiments, and the flgK strain
was grown on LB agar containing 10 g/ml of tetracycline for positive selection
of the bacteria carrying this mutation. The number of viable biofilm bacteria was
enumerated by CFU on LB agar for both strains. To further demonstrate that the
biofilm-specific killing effect was due to the absence of functional flagella, three
other strains, carrying mutations in flgD, fliC, and fliF, were also tested. These
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mutant strains were obtained from the nonredundant P. aeruginosa PA14 mutant
library developed by Liberati and colleagues (38).
Reagents. Recombinant human gamma interferon (IFN-␥; 100 g) was purchased from Southern Biotech (Birmingham, AL), and recombinant human
tumor necrosis factor alpha (TNF-␣; 50 g) was purchased from Millipore
(Billerica, MA). The cytokines were resuspended in 1⫻ phosphate-buffered
saline and distilled H2O, respectively. Human LTF (5 mg) was purchased from
Sigma-Aldrich (St. Louis, MO). Hanks balanced salt solution (HBSS), 1 M
HEPES buffer, and bacterial growth medium were purchased from Fisher Scientific (Pittsburgh, PA).
Growth of Pseudomonas aeruginosa. P. aeruginosa wild-type PA14 and the flgK
mutant were cryogenically stored, and aliquots were used for all experiments.
PA14 and flgK were streaked on LB agar alone and LB agar with 10 g/ml
tetracycline, respectively, for 24 h at 37°C. Single colonies of each were used to
inoculate 10 ml of sterile LB broth, which was incubated at 37°C under constant
agitation overnight. After sufficient growth, the culture was diluted 1:100 in fresh
LB broth and incubated for 3 h, until the culture reached the midpoint of
exponential growth.
Static biofilm growth in microtiter plates. Biofilms were grown in 96-well
polyvinyl chloride (PVC) plates (Falcon) or in 24-well polystyrene plates (Falcon) as previously described (35). The 3-h cultures described above were further
diluted 1:50 in fresh LB medium, and 100 l of the inoculated medium was
added to a sterile 96-well PVC plate or 400 l was added to a 24-well polystyrene
plate, depending on the assay. The plates were covered and incubated at 37°C
with no agitation for 24 h. These biofilms were used for leukocyte killing assays
as described below.
Isolation of human peripheral blood leukocytes. Human leukocyte isolation
was performed as previously described (35). Healthy human donors were used as
sources for peripheral blood leukocytes after reading and signing donor consent
forms (protocol approved by the NAU Human Subjects IRB). Human blood was
collected into acid citrate Vacutainer tubes (Becton, Dickinson and Company,
Franklin, NJ) and centrifuged for 12 min at 500 ⫻ g, and the peripheral blood
leukocytes and autologous plasma were collected. The remaining erythrocytes in
the buffy coat were lysed by hypotonic treatment, followed by rapid dilution in
HBSS. The purified leukocytes were counted and resuspended in an appropriate
volume of HBSS and 50% autologous plasma to yield a final leukocyte concentration of 5 ⫻ 107 cells/ml. The critical neutrophil concentration was previously
determined (37); however, we designed our studies so that the concentration of
human peripheral leukocytes was fivefold greater because we used a mixed
concentration of leukocytes and because biofilms have been shown to be inherently resistant to leukocyte killing factors (35).
In order to determine human leukocyte cytokine cross talk, subpopulations of
leukocytes were fractionated by use of a density gradient as previously described
(35). Briefly, 10 to 15 ml of freshly collected human blood was diluted 1:2 with
HBSS, underlaid first with 10 ml of 1.077 g/ml Histopaque (Sigma-Aldrich), and
then 10 ml of 1.119 g/ml Histopaque (Sigma-Aldrich) in a sterile 50-ml conical.
The tubes were centrifuged at 700 ⫻ g for 30 min, and the resulting 1.077 and
1.119 buffy coats containing mononuclear cells and neutrophils, respectively,
were collected into separate, sterile 50-ml conicals. If there were remaining
erythrocytes, they were lysed by hypotonic treatment for 10 s and rapidly diluted
with HBSS to a final volume of 50 ml. The purified subpopulations of leukocytes
were counted and resuspended in an appropriate volume of HBSS and pooled
human serum to yield 1 ⫻ 107 cells/ml. The cells were used in a transwell biofilm
killing assay, as described below. For all biofilm killing assays, 10 mM of HEPES
buffer was added to maintain a constant pH throughout the assay.
Biofilm killing assay. Biofilm challenge experiments were performed as previously described (35). To determine whether the flgK strain was more susceptible to human leukocyte killing than PA14, the biofilms were incubated with an
appropriate concentration of a mixed population or purified subpopulations of
leukocytes and IFN-␥ at a final concentration of 50 units/ml for 4 h at 37°C. Prior
to challenge by leukocytes, microtiter plates containing biofilms were inverted
and the nonadherent cells were washed away. Following this, 100 l of the mixed
leukocyte population or the respective subpopulations was added in triplicate to
PA14 and flgK biofilms. Control treatments included challenge with LB medium
and HBSS-50% autologous plasma. Both of the control treatments were also
added at a volume of 100 l in triplicate wells. After the 4-h challenge, the PVC
plates containing biofilms were inverted, gently sonicated in a Microhorn sonicator (Misonix, Farmingdale, NY), and serially diluted 10-fold in sterile deionized water. Serial dilutions were plated on LB agar in triplicate 20-l spots and
allowed to grow for 12 to 18 h at 37°C. CFU were counted and reported as
CFU/ml. To determine whether TNF-␣ played a role in the activation of neutrophils, it was added at a final concentration of 125 pg/ml into the wells and
biofilm killing was quantified by CFU/ml as described above. An analysis by
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FIG. 1. Schematic cartoon of the transwell biofilm killing assay.
Note that cells of the innate immune system can be added either to the
top chamber of the insert with the artificial membrane (no biofilm
physical contact) or to the bottom chamber (physical biofilm contact)
and that, because of the pore size of the inserts (0.4 m), transmigration is extensively limited. Supernatant fluid can then be analyzed for
components of innate immunity that are known for their bactericidal
activity.

trypan blue exclusion showed that leukocytes associated with biofilm bacteria did
not undergo extensive cell death by this protocol (data not shown).
Transwell biofilm killing assay. To establish the killing mechanism(s), we
developed a novel transwell assay where the specific leukocyte subpopulations
could be separated from one another and the supernatant fluid assayed for the
presence of bioactive molecules. Biofilms were grown in 24-well polystyrene
plates (Falcon) for 24 h at 37°C. Following incubation, the plates were inverted
and nonadherent cells washed away. Isolated subpopulations of leukocytes
(mononuclear cells and neutrophils) were obtained via the double Histopaque
procedure described above. Tissue culture inserts with a pore size of 0.4 m were
placed into each well containing biofilm bacteria of the 24-well plate. The
purified leukocyte subpopulations were kept separate through the use of the
tissue culture inserts. Each treatment consisted of alternating subpopulations of
leukocytes, at a volume of 200 l each for 400 l total volume, either on the top
of the membrane or directly onto the biofilm bacteria (e.g., mononuclear cells on
top of the membrane, neutrophils directly on the biofilm). For clarity, we have
included a cartoon schematic of this experimental design in Fig. 1. Recombinant
IFN-␥ (50 U/ml) was added to each well to induce macrophage activation. To
determine if TNF-␣ played a role in neutrophil activation, recombinant TNF-␣
was also added to some treatments at a final concentration of 125 pg/ml. Control
treatments included LB medium and HBSS-50% pooled human serum. Biofilm
bacteria were quantified as described above, and the number of CFU/ml was
reported. In order to verify that cytokine cross talk played a role in bacterial
biofilm killing, the leukocytes were treated with 1 g/ml brefeldin A (SigmaAldrich), which inhibits secretory pathways in eukaryotes, including cytokine
release. Briefly, the leukocytes were added to the biofilms in the presence of
brefeldin A, the biofilm was challenged for 6 h, viable bacteria were serially
diluted, and the CFU were counted and reported.
NO, LTF, and MPO quantification assays. To determine which reactive moiety(ies) played a role in biofilm bacterial killing, assays were employed for
various known neutrophil antibacterial compounds. NO production was quantified using a Griess reagent kit (Promega), following the manufacturer’s protocol.
Briefly, supernatant fluid was obtained from the biofilm treatment after 6 h of
incubation and centrifuged at maximum speed for 10 min to remove leukocytes
and bacterial cells. Samples were incubated with Griess reagent for 20 min and
read on an Opsys MR microplate spectrophotometer (Dynex Technologies) at
550 nm. Unknown samples were compared to a standard curve. LTF and MPO
production were quantified using enzyme-linked immunosorbent assay (ELISA)
kits obtained from Calbiochem. The assays were run per the manufacturer’s
protocol. Briefly, supernatant fluid was obtained from the tissue culture insert
and the 24-well plate and centrifuged at maximum speed for 10 min. The
supernatant was diluted if necessary and added to the wells of the 96-well plate
containing monoclonal antibodies. After incubation, the wells were washed five
times with wash buffer, and a secondary antibody-horseradish peroxidase conjugate was added and then incubated for 15 min at 37°C. The wells were washed
again, and substrate was added. Color change was measured on a microplate
spectrophotometer (Dynex Technologies) at 405 nm (MPO) and 420 nm (LTF).
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FIG. 2. P. aeruginosa biofilm bacteria lacking flagella are killed by
human leukocytes, whereas the parental strain PA14 biofilm bacteria
are not. Graphic representation of CFU/ml of flgK (black bars) and
PA14 (gray bars) biofilm bacteria after treatment with medium control
(LB) (1), HBSS plus 50% autologous human plasma (2), human leukocytes in HBSS containing 50% autologous plasma (3), and leukocytes in HBSS containing 50% autologous plasma plus IFN-␥ (50
U/ml) (4). Percent survival was calculated by normalizing the LB
medium control to equal 100% survival and is listed above the appropriate treatment. ⴱ, P ⬍ 0.001 for the leukocytes plus IFN-␥ treatment
compared to all other treatments. Data are representative of the results from three separate experiments with variable blood donors.

Unknown samples were compared to a standard curve, and the experimental
concentration of LTF or MPO was calculated.
LTF killing assay. To determine if LTF alone was responsible for the killing
of flgK biofilm bacteria, recombinant human LTF was added to the biofilm in the
absence of leukocytes. The optimal concentration of LTF for biofilm killing was
determined by adding 100 l LTF at various concentrations. Control treatments
included LB medium and sterile deionized H2O containing no LTF. After 6 h of
incubation, viable bacteria were enumerated by CFU. After determining the
optimal concentration for bacterial biofilm killing, the effects of recombinant
LTF were compared to those of natural LTF. Briefly, mixed population leukocytes were isolated, and 100 l was placed into triplicate wells containing biofilm
bacteria. Also, 100 l recombinant LTF at 1 g/ml was added in triplicate to the
biofilm. Control treatments included LB medium and 50% HBSS with 50%
autologous plasma. The biofilms were challenged for 6 h at 37°C, and viable
bacteria were serially diluted and the CFU counted as described above.
Statistical analysis. An analysis was performed using JMP IN statistical software. The results are presented as means ⫾ standard errors of the means and
were analyzed using Student’s t test. A P value of ⬍0.05 was considered statistically significant.

RESULTS
Effect of human leukocytes on PA14 and flgK mutant P.
aeruginosa biofilm bacteria. P. aeruginosa biofilm bacteria that
lack flagella are killed when challenged by whole-blood leukocytes, and optimal killing occurs in the presence of exogenous
IFN-␥ (Fig. 2). After 4 h of challenge, greater than a log
reduction in viable biofilm bacteria was observed by CFU enumeration. In contrast, even in the presence of IFN-␥, biofilm
bacteria from the parental strain (PA14) were not killed. The
killing of flgK biofilm bacteria was significant compared to both
LB treatment (positive control for growth) and HBSS plus
50% autologous plasma (leukocyte medium control showing
nutrient limitation of the medium and killing activity of any
bactericidal components in the human plasma). Challenging
the biofilms of either the parental strain or mutant for up to
24 h did not increase the number of bacteria killed under any
experimental setting (4; data not shown). Additional studies
for which biofilms of PA14 and flgK were grown for 8 h, and
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FIG. 3. Neutrophils, in the presence of exogenous TNF-␣, are primarily responsible for the killing of flgK biofilm bacteria. Graphic
representation of CFU/ml of flgK biofilm bacteria after challenge by
specific leukocyte subpopulations. 1, LB treatment; 2, HBSS plus 50%
autologous plasma; 3, mononuclear cells; 4, neutrophils; 5, mononuclear cells plus neutrophils; 6, mononuclear cells plus TNF-␣ (125
pg/ml); 7, neutrophils plus TNF-␣; 8, mononuclear cells, neutrophils,
and TNF-␣. Percent survival was calculated by normalizing the LB
medium control to equal 100% survival and is listed above the appropriate treatment. ⴱ, P ⬍ 0.01 for bars 4 to 8 compared to all other
treatments. Data are representative of the results from three separate
experiments with variable blood donors.

challenged by freshly isolated human leukocytes as described
above, demonstrated that the flgK biofilm bacteria were more
susceptible to leukocyte killing, even at this early time point in
biofilm development (data not shown). Finally, planktonic
PA14 and flgK biofilm bacteria were challenged by freshly
isolated human leukocytes and no differences in the amount of
killed bacteria were observed (data not shown). Collectively,
these studies suggest that the susceptibility of flgK bacteria to
human leukocytes is a biofilm-specific paradigm. However, by
the approaches we have taken here, we cannot rule out subtle
impacts that the flagellar mutation may have on biofilm physiology, which may have an effect on the immune response to
this flagellar negative population.
Killing of flgK biofilm bacteria requires both mononuclear
cells, neutrophils, and cytokines. To determine if there was a
leukocyte phenotype that was responsible for the killing of the
flgK biofilm bacteria, mononuclear cells (primarily monocytes
and lymphocytes) and neutrophils were separated by density
gradient centrifugation. PA14 and flgK biofilm bacteria were
then challenged for 4 h and viable bacteria enumerated by
CFU. Subsequent to the challenge, we observed moderate
killing in the presence of mononuclear cells (Fig. 3, bar 3) that
was not statistically significant. Conversely, challenge by neutrophils alone resulted in an approximately 1-log reduction of
viable biofilm bacteria (Fig. 3, bar 4). However, optimal killing
was observed when mononuclear cells, neutrophils, and exogenous TNF-␣ were utilized to challenge the flgK biofilm bacteria (Fig. 3, bar 8), although neutrophils and TNF-␣ also
induced a strong biofilm killing effect. A previous report by a
group in Denmark demonstrated that P. aeruginosa, with an
intact quorum-sensing system, rapidly killed human neutrophils by rhamnolipid secretion (6, 28). To determine if this
occurred in our assay system, the biofilm and neutrophils were
gently sonicated, the resuspended nonattached population of
bacteria and cells pipetted onto a hemocytometer, and neutro-
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FIG. 4. Three additional mutations in the flagellar operon lead to
biofilm bacterial susceptibility. Graphic representation of CFU/ml of
biofilm bacterial viability of the parental strain PA14 and mutations in
flgD, fliC, and fliF after challenge by human leukocytes. 1, LB treatment; 2, HBSS plus 50% autologous plasma; 3, total leukocytes plus
TNF-␣. Percent survival was calculated by normalizing the LB medium
control to equal 100% survival and is listed above the appropriate
treatment. ⴱ, P ⬍ 0.001 for the leukocytes plus TNF-␣ treatment
compared to all other treatments. Data are representative of the results from two separate experiments with variable blood donors.

phil viability tested by trypan blue exclusion. In our assay
system, neutrophil viability remained ⬎90% after 4 to 6 h of
biofilm challenge (data not shown).
Optimal killing of biofilm bacteria was dependent upon the
presence of functional flagella. To confirm the specific role of
flagella in the protection of biofilms from leukocyte killing, we
tested the following three additional strains carrying mutations
that disrupt flagellar synthesis: the flgD, fliC, and fliF strains
(38, 45). The biofilms of these three additional strains, plus the
parental strain PA14, were grown and challenged by leukocytes
in the presence of recombinant TNF-␣ and the viable bacteria
determined as described above. All three of these mutants
were susceptible to human leukocyte killing (Fig. 4). At least a
log reduction in viable bacteria was observed for all three
mutants, and the fliF mutant demonstrated hypersusceptibility
to killing under these conditions (Fig. 4, bar 3). These data
confirm that the absence of flagella mediates biofilm bacterial
susceptibility to components of the human innate immune
system. Because all of these genes are within a large operon,
complementation studies would have been difficult and were
not attempted. However, because the flgD gene is in the same
operon as flgK, and the fliC and fliF mutations are in a distinct
flagellar operon, the aggregate analysis of these mutant strains
has effectively allowed us to eliminate potential issues confounding the interpretation of our findings, including secondary mutations and polarity. We are currently attempting to
decipher why the fliF mutant exhibited hypersusceptibility to
components of the innate immune system.
Cytokine secretion by leukocytes is requisite for the killing
of flgK biofilm bacteria. Since the data suggested that both
IFN-␥ and TNF-␣ were important cytokines that lead to the
killing of flgK biofilm bacteria, we tested whether the ability to
secrete cytokines was requisite for the killing of biofilm bacteria. For these studies, the flgK biofilm bacteria were challenged
with whole-blood leukocytes (mononuclear cells and neutrophils) in the presence and absence of brefeldin A, which blocks
the secretion of cytokines from human leukocytes (10). As
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FIG. 5. Brefeldin A, which prevents the secretion of cytokines,
blocked the killing of flgK biofilm bacteria. Graphic representation of
CFU/ml of flgK biofilm bacteria in the presence (gray) or absence
(black) of brefeldin A. 1, LB treatment; 2, HBSS plus 50% autologous
plasma; 3, leukocytes plus IFN-␥ (50 U/ml). Percent survival was calculated by normalizing the LB medium control to equal 100% survival
and is listed above the appropriate treatment. ⴱ, P ⬍ 0.001 for the
leukocytes plus IFN-␥ treatment compared to all other treatments.
Data are representative of the results from three separate experiments
with variable blood donors.

Fig. 5 shows, in the presence of brefeldin A, no biofilm
bacterial killing was observed.
Cytokine cross talk between mononuclear cells and neutrophils is necessary for the killing of flgK biofilm bacteria. Cytokine cascades occur in response to many types of stimuli, and
cross talk often occurs between cells so that the effector functions of those cells are enhanced. In order to decipher if cytokine cross talk between mononuclear cells and neutrophils was
required for optimal biofilm bacterial killing, we developed a
novel assay that employed tissue culture transwell inserts. This
assay was described in detail in Materials and Methods (Fig. 1).
Briefly, by utilizing culture inserts with a pore size of 0.4 m,
we were able to physically isolate the specific leukocyte populations so that only proteins (such as cytokines) and other small
molecules could diffuse through the membrane and act upon
whatever cell population was present on the other side of the
membrane. By utilizing this approach, we demonstrated that
the maximum killing of flgK biofilm bacteria occurred when
mononuclear cells were in the tissue culture insert (top), without access to the bacterial biofilm itself, and neutrophils were
in direct contact with the biofilm (Fig. 6, bar 6). All combinations of leukocyte subsets and cytokines were assayed and only
the most relevant combinations are shown in Fig. 6. Additionally, ELISAs were utilized to determine that TNF-␣ was produced by the mononuclear cell fraction and diffused across the
membrane into the bottom chamber (data not shown). The
difference in killing activity between the combination in lanes
5 and 6 may be attributed to subtle differences in the activity of
recombinant human TNF-␣ versus TNF-␣ naturally produced
from peripheral blood mononuclear cells, although this was
not directly tested in our study.
Neutrophil LTF is induced by TNF-␣ and leads to the killing of flgK biofilm bacteria. One of the other important aspects
of the novel biofilm killing assay described above is that it
allows for the evaluation of effector molecules from leukocytes,
such as MPO, NO, and LTF. Utilizing this approach, we assayed for the presence of these innate effector compounds by
standard ELISA. Interestingly, we did not observe any signif-
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FIG. 6. Cytokine cross talk between mononuclear cells and neutrophils leads to the killing of flgK biofilm bacteria by neutrophils. Graphic
representation of CFU/ml of flgK biofilm bacteria after challenge by
specific leukocyte subpopulations. 1, LB treatment; 2, HBSS plus 50%
autologous plasma; 3, mononuclear cells and neutrophils plus TNF-␣ in
the top chamber; 4, mononuclear cells and neutrophils plus IFN-␥ and
TNF-␣ in the bottom chamber; 5, mononuclear cells plus IFN-␥ in the top
chamber and neutrophils and TNF-␣ in the bottom chamber; 6, mononuclear cells plus IFN-␥ in the top chamber and neutrophils on the
bottom. Percent survival was calculated by normalizing the LB medium
control to equal 100% survival and is listed above the appropriate
treatment. ⴱ, P ⬍ 0.001 for bar 6 compared to all other treatments.
Data are representative of the results from three separate experiments
with variable blood donors. Refer to Materials and Methods for the
details of the transwell assay.

icant difference in the production of MPO and NO compared
to wells where leukocytes were incubated in the absence of
bacteria. However, we did see dramatic release of the ironbinding protein lactoferrin (Fig. 7). The largest amount of LTF
was observed by ELISA in the experimental design where the
optimal killing was observed (Fig. 6, bar 6), when mononuclear
cells were in the tissue culture insert, in the presence of IFN-␥,
and neutrophils were in direct contact with the biofilm (Fig. 7,
bar 6). Endogenous LTF levels from neutrophils incubated
alone, in the absence of biofilm bacteria, were ⬃80 ng/ml (data

FIG. 7. LTF, a bacteriostatic and bactericidal component of the
innate immune system, is produced in response to P. aeruginosa biofilms and is associated with biofilm bacterial killing. Graphic representation of LTF (ng/ml) produced during challenge of flgK by specific
leukocyte subpopulations. 1, mononuclear cells and neutrophils plus
IFN-␥ and TNF-␣ in the top chamber; 2, neutrophils plus IFN-␥ in the
top chamber; 3, neutrophils plus TNF-␣ in the top chamber; 4, mononuclear cells plus IFN-␥ in the top chamber and neutrophils plus
TNF-␣ in the bottom chamber; 5, mononuclear cells and neutrophils
plus IFN-␥ and TNF-␣ in the bottom chamber; 6, mononuclear cells
plus IFN-␥ in the top chamber and neutrophils in the bottom chamber.
Data are representative of the results from three separate experiments
with variable blood donors. Refer to Materials and Methods for the
details of the transwell assay.
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FIG. 8. Addition of purified, exogenous LTF alone results in the
killing of flgK biofilm bacteria. Graphic representation of CFU/ml of
flgK biofilm bacteria after challenge by specific concentrations of purified, recombinant human LTF. 1, LB treatment; 2, water (solvent for
purified LTF); 3, 50 ng/ml LTF; 4, 100 ng/ml LTF; 5, 500 ng/ml LTF;
6, 1,000 ng/ml LTF; 7, mononuclear cells and neutrophils plus IFN-␥
(measured at ⬃900 ng/ml LTF). Percent survival was calculated by
normalizing the LB medium control to equal 100% survival and is
listed above the appropriate treatment. Data are representative of the
results from three separate experiments with variable blood donors.

not shown). The main differences between lanes 5 and 6 in
this figure could be attributable to subtle activity differences
between recombinant and native TNF-␣. These results complemented the findings of Singh and colleagues where they
demonstrated that LTF inhibited P. aeruginosa biofilm development but did not result in bacterial killing (52).
Purified LTF kills flgK biofilm bacteria in a dose-dependent
manner. In order to determine if the bactericidal effect of LTF
was dose-dependent, we challenged flgK biofilm bacteria with
increasing concentrations of recombinant human LTF. Although minimal killing was observed at 100 and 500 ng/ml of
LTF, significant killing was observed when 1,000 ng/ml was
used to challenge the biofilm bacteria (Fig. 8, bar 6). These
data demonstrated that the concentration of LTF was important in its ability to act as a bactericidal compound. As a
control for these studies, mononuclear cells, neutrophils and
IFN-␥ were used to challenge the flgK biofilm bacteria, which
as reported above and here, also resulted in biofilm bacterial
killing (Fig. 8, bar 7). The amount of LTF produced by neutrophils in these assays averaged ⬃900 ng/ml in these studies
(Fig. 7 and data not shown). Collectively, these data demonstrated that LTF was responsible for killing flgK biofilm bacteria and that the killing concentration of LTF was well within
the physiological range of the amount produced by human
neutrophils (see Discussion below).
LTF is responsible for killing flgK, but not PA14, biofilm
bacteria. Finally, we wanted to determine the extent of LTFmediated killing of the flgK biofilm bacteria versus the parental
strain, PA14. For these studies, biofilms were grown in 96-well
plates and challenged with mononuclear cells, neutrophils, and
IFN-␥ for 4 h, and viable bacteria were enumerated by CFU.
As expected, the flgK biofilm bacteria were killed by recombinant human LTF (1,000 ng/ml [Fig. 9, bar 3]) and by LTF
produced by the neutrophils (Fig. 9, bar 4). However, the
parental biofilm formed by strain PA14 was resistant to both
the purified LTF and challenge by human leukocytes (Fig. 9).
Although a reduction in viable parental biofilm bacteria was
observed, this effect was not specific to LTF activity as there
was no difference between LTF challenge and exposure to
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FIG. 9. LTF is bactericidal against flgK biofilm bacteria but not that
of the parental strain PA14. Graphic representation of CFU/ml of
PA14 (gray) and flgK (black) biofilm bacteria after challenge by purified LTF and human leukocytes. 1, LB treatment; 2, HBSS plus 50%
autologous plasma; 3, 1,000 ng/ml purified LTF; 4, mononuclear cells
and neutrophils plus IFN-␥. Percent survival was calculated by normalizing the LB medium control to equal 100% survival and is listed
above the appropriate treatment. Data are representative of the results
from three separate experiments with variable blood donors.

HBSS-50% autologous plasma. Collectively, these data represent an in-depth analysis of the innate immune response to
biofilm bacteria and identify another genetic basis for biofilm
resistance to human-host components.
DISCUSSION
Previously, we have characterized genetically mediated resistance of P. aeruginosa biofilm bacteria to human leukocytes
(35). Here we have extended those studies to demonstrate that
the flgK gene in P. aeruginosa is important for protection
against innate immune cells and their effector products (LTF).
In the presence of IFN-␥, whole-blood leukocytes were able to
kill P. aeruginosa biofilm bacteria that lacked this gene. The
killing of flgK biofilm bacteria required the presence of mononuclear cells, the secretion of TNF-␣ from this leukocyte population, and the resultant production of bactericidal concentrations of LTF from neutrophils. These data complement the
observations of Singh and colleagues (52) on LTF preventing
P. aeruginosa biofilm development, while showing that physiological concentrations of LTF can be bactericidal, and document the importance of cytokine cross talk between immune
cells to produce antibiofilm compounds.
As with our previous study, the presence of specific cytokines was important as brefeldin A, which blocks the secretion
of cytokines, absolved the killing of the flgK biofilm bacteria.
Cytokine cross talk between the cells of the immune system has
been known for some time (e.g., the Th1 versus Th2 paradigm)
and is often vital to the generation of appropriate and protective
immune responses. For this study, the release of the cytokine
TNF-␣ by mononuclear cells was essential to neutrophil-mediated killing through the secretion of bactericidal concentrations
of LTF.
During biofilm development, the presence of flagella in P.
aeruginosa is tightly regulated (48, 49). As planktonic cells
encounter a surface, exhibiting swarming and twitching motility, these bacteria contain functional flagella. Once firm attachment has taken place, in as little as 6 h, flagella are dramatically
downregulated from the surface of the attached bacteria. However, as the biofilm life cycle continues, and mature biofilm
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clusters proceed to individual dispersed cells, flagella are again
upregulated (48, 49). Importantly, these detached cells exhibit
similar antibiotic resistance as those in the parental biofilm,
and this developmental paradigm does not depend upon
growth inside the CF lung (19). The targeting of the flagellumnegative population of P. aeruginosa biofilm with exogenous
LTF, or by the immunomodulation of cytokines, may improve
the host’s ability to kill these organisms. Although the parental
biofilm was not killed by physiological concentrations of purified, recombinant LTF, it may be that the induction of this
defense in vivo, in the presence of fully activated immune cells,
would lead to improved biofilm clearance. Biofilm populations
of P. aeruginosa are heterogeneous and some do not express
flagella (34, 57). By combining a targeted, adjuvant-based approach to enhance the appropriate immune response to these
cells, it may be possible to reduce the bacterial load in P.
aeruginosa biofilm infections of indwelling medical devices,
burn wounds, chronic wounds, and potentially the lungs of CF
patients.
LTF is a nonheme iron-binding glycoprotein that has both
bacteriostatic and bactericidal activity (17). In a previous study,
Singh and colleagues demonstrated that LTF, at relatively low
concentrations, successfully prevented P. aeruginosa biofilm
formation in vitro but was not bactericidal to the microorganisms (52). However, our studies on preformed P. aeruginosa
biofilms demonstrated that concentrations 20 times less than
the optimal subinhibitory concentration listed in their paper
killed biofilm bacteria lacking intact flagella. Importantly, we
characterized the amount of LTF produced by purified human
neutrophils in our assays and confirmed that these physiological concentrations were responsible for biofilm bacterial killing by the addition of recombinant human LTF. At physiologically relevant killing levels (⬃900 ng/ml), purified LTF
resulted in an approximately 1-log reduction in viable bacteria.
Presumably, as published reports have shown, LTF was active
against the biofilm bacteria by binding to lipopolysaccharide
causing disruption of the bacterial membrane (3, 17, 43). We
are currently characterizing the effect of LTF on P. aeruginosa
biofilm bacteria.
Inflammation, induced by either bacteria or other insults,
causes the release of cytokines. One early inflammatory cytokine is IFN-␥, and its main cellular sources are T cells, NK
cells, and monocytes/macrophages (8). T cells are the most
notable secretors of IFN-␥ when they encounter antigen-presenting cells and major histocompatibility complex class II.
However, macrophages and NK cells secrete IFN-␥ in the
absence of costimulation from other immune cells. If present,
neutrophils can respond to IFN-␥ in a number of ways, including by the secretion of LTF from specific granules (16, 18). For
the studies described here, we believe that macrophages are
activated directly, potentially by the interaction of TLR4 with
lipopolysaccharide or by activation with exogenous IFN-␥, and
secrete TNF-␣, which in turn induces neutrophils to secrete
LTF, subsequently killing biofilm bacteria. Although not directly related to bacterial infection, a previous report demonstrated that lung macrophages were able to respond to external
stimuli, resulting in cytokine secretion, which directly leads to
secretion of the azurophilic component elastase (42).
Bacterial biofilms of Pseudomonas aeruginosa are the common cause of chronic infections in CF patients as well as other
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patients who exhibit some form of immune system suppression
(e.g., burn wounds). Biofilm communities of P. aeruginosa have
been observed in chronic wounds and burn wounds, where they
are a leading cause of bacterial sepsis and mortality (5, 7, 50).
Additionally, P. aeruginosa will form biofilms on implanted
medical devices including prostheses, catheters, and central
venous lines, among others (51). A 2005 case study by Germiller and colleagues showed prominent P. aeruginosa infection on cochlear implants affecting otherwise healthy individuals and individuals with previous cases of chronic otitis media
(20). These infections are notoriously hard to treat because
these communities are inherently resistant to antibiotics and to
the host’s immune system. By deciphering the molecular approaches that biofilms of P. aeruginosa utilize to evade components of the human immune system, we have potentially
identified either biofilm-specific vaccine candidates or potential therapeutic targets for biofilm adjuvant therapy. For example, to coincide with the biofilm-specific genetic regulation
of flagella in P. aeruginosa, it may be possible to elicit bactericidal concentrations of human LTF from neutrophils recruited to the infection site either by the activation of resident
macrophages or through TNF-␣ immunotherapy. The in vivo
production of LTF may then reduce the amount of biofilm
colonization of the lung or other tissue resulting in a decreased
disease burden for the patient. This approach has been suggested to improve chemotherapy for cancer in humans (4).
Irrespective of the approach, our studies clearly indicate the
importance of the human immune response to biofilm infections and suggest that in addition to the massive effort to
discover novel antibiofilm antibiotics, understanding the role
of the immune system in biofilm infections is vital to reducing
the burden of these infections.
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